1.515
1.34%
+0.025
Scilex Holding Company stock is currently priced at $1.515, with a 24-hour trading volume of 796.54K.
It has seen a +1.34% increased in the last 24 hours and a +88.75% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.50 pivot point. If it approaches the $1.56 resistance level, significant changes may occur.
Previous Close:
$1.49
Open:
$1.5
24h Volume:
796.54K
Market Cap:
$181.68M
Revenue:
$46.74M
Net Income/Loss:
$-114.33M
P/E Ratio:
-2.52
EPS:
-0.6012
Net Cash Flow:
$-21.04M
1W Performance:
+38.53%
1M Performance:
+88.75%
6M Performance:
+17.97%
1Y Performance:
-79.73%
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding Company
Sector
Industry
Phone
650-516-4310
Address
960 San Antonio Road, Palo Alto
Scilex Holding Company Stock (SCLX) Latest News
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
GlobeNewswire Inc.
Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically - Simply Wall St
Simply Wall St
Scilex Holding Company (NASDAQ:SCLX) Analysts Just Cut Their EPS Forecasts Substantially - Yahoo Finance
Yahoo Finance
SCLX Shares Experience Surge in Value – Knox Daily - Knox Daily
Knox Daily
Pharma Shares Pop After Securing $100M Of Financing - The Globe and Mail
The Globe and Mail
Pharma Shares Pop After Securing $100M Of Financing - The Globe and Mail
The Globe and Mail
Scilex Holding Company Stock (SCLX) Financials Data
Scilex Holding Company (SCLX) Revenue 2024
SCLX reported a revenue (TTM) of $46.74 million for the quarter ending December 31, 2023, a +22.90% rise year-over-year.
Scilex Holding Company (SCLX) Net Income 2024
SCLX net income (TTM) was -$114.33 million for the quarter ending December 31, 2023, a -389.35% decrease year-over-year.
Scilex Holding Company (SCLX) Cash Flow 2024
SCLX recorded a free cash flow (TTM) of -$21.04 million for the quarter ending December 31, 2023, a +1.04% increase year-over-year.
Scilex Holding Company (SCLX) Earnings per Share 2024
SCLX earnings per share (TTM) was -$1.29 for the quarter ending December 31, 2023, a -646.53% decline year-over-year.
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Cap:
|
Volume (24h):